FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313244876> ?p ?o ?g. }

• W4313244876 endingPage "71" @default.
• W4313244876 startingPage "71" @default.
• W4313244876 abstract "Since the start of the SARS-CoV-2 pandemic, several treatments have been proposed to prevent the progression of the disease. Currently, three antiviral (molnupiravir, nirmaltrevir/r, remdesivir) and two monoclonal antibodies (casirivimab/imdevimab and sotrovimab) are available in Italy. Therefore, we aimed to evaluate the presence of risk factors associated with disease progression. We conducted a retrospective cohort study, including all patients with a confirmed diagnosis of SARS-CoV-2 evaluated between 01/01/2022 ad 10/05/2022 by our Unit of Infectious Diseases in Sassari. We defined disease progression as the necessity of starting O2 therapy. According to AIFA (Italian Medicines Agency) indications, preventive treatment was prescribed in patients with recent symptoms onset (≤five days), no need for oxygen supplementation, and risk factors for disease progression. Subgroup differences in quantitative variables were evaluated using Student’s t-test. Pearson chi-square or Fisher’s exact tests were used to assess differences for qualitative variables. Multivariate logistic regression modelling was performed to determine factors associated with progression. A two-tailed p-value less than 0.05 was considered statistically significant. All statistical analyses were performed with STATA version 17 (StataCorp, College Station, TX, USA). We included 1145 people with SARS-CoV-2 diagnosis, of which 336 (29.3%) developed severe disease with oxygen supplementation. In multivariate logistic regression analysis, age, dementia, haematologic tumors, heart failure, dyspnoea or fever at first evaluation, having ground glass opacities or consolidation at the first CT scan, and bacteria coinfection were associated with an increased risk of disease progression. Vaccination (at least two doses) and early treatment with antiviral or monoclonal antibodies were associated with a lower risk of disease progression. In conclusion, our study showed that vaccination and early treatment with antiviral and/or monoclonal antibodies significantly reduce the risk of disease progression." @default.
• W4313244876 created "2023-01-06" @default.
• W4313244876 creator A5012523632 @default.
• W4313244876 creator A5015006843 @default.
• W4313244876 creator A5040814048 @default.
• W4313244876 creator A5042226875 @default.
• W4313244876 creator A5046108759 @default.
• W4313244876 creator A5049419930 @default.
• W4313244876 creator A5049528108 @default.
• W4313244876 creator A5050154783 @default.
• W4313244876 creator A5063078489 @default.
• W4313244876 creator A5068695530 @default.
• W4313244876 creator A5071827015 @default.
• W4313244876 creator A5078656388 @default.
• W4313244876 creator A5079913204 @default.
• W4313244876 creator A5082578432 @default.
• W4313244876 date "2022-12-27" @default.
• W4313244876 modified "2023-10-01" @default.
• W4313244876 title "Impact of Early SARS-CoV-2 Antiviral Therapy on Disease Progression" @default.
• W4313244876 cites W3004280078 @default.
• W4313244876 cites W3014003872 @default.
• W4313244876 cites W3016348548 @default.
• W4313244876 cites W3019953082 @default.
• W4313244876 cites W3024806323 @default.
• W4313244876 cites W3025870082 @default.
• W4313244876 cites W3027667132 @default.
• W4313244876 cites W3046760923 @default.
• W4313244876 cites W3090921503 @default.
• W4313244876 cites W3091811816 @default.
• W4313244876 cites W3111255098 @default.
• W4313244876 cites W3138604429 @default.
• W4313244876 cites W3201233035 @default.
• W4313244876 cites W4200051875 @default.
• W4313244876 cites W4200206478 @default.
• W4313244876 cites W4205483821 @default.
• W4313244876 cites W4210642183 @default.
• W4313244876 cites W4226236384 @default.
• W4313244876 cites W4281766393 @default.
• W4313244876 cites W4281988270 @default.
• W4313244876 cites W4286209601 @default.
• W4313244876 cites W4289339206 @default.
• W4313244876 cites W4293198902 @default.
• W4313244876 cites W4293248842 @default.
• W4313244876 cites W4293280590 @default.
• W4313244876 cites W4297458151 @default.
• W4313244876 cites W4297876464 @default.
• W4313244876 cites W4303423758 @default.
• W4313244876 cites W4306292827 @default.
• W4313244876 cites W4306673647 @default.
• W4313244876 doi "https://doi.org/10.3390/v15010071" @default.
• W4313244876 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36680111" @default.
• W4313244876 hasPublicationYear "2022" @default.
• W4313244876 type Work @default.
• W4313244876 citedByCount "11" @default.
• W4313244876 countsByYear W43132448762023 @default.
• W4313244876 crossrefType "journal-article" @default.
• W4313244876 hasAuthorship W4313244876A5012523632 @default.
• W4313244876 hasAuthorship W4313244876A5015006843 @default.
• W4313244876 hasAuthorship W4313244876A5040814048 @default.
• W4313244876 hasAuthorship W4313244876A5042226875 @default.
• W4313244876 hasAuthorship W4313244876A5046108759 @default.
• W4313244876 hasAuthorship W4313244876A5049419930 @default.
• W4313244876 hasAuthorship W4313244876A5049528108 @default.
• W4313244876 hasAuthorship W4313244876A5050154783 @default.
• W4313244876 hasAuthorship W4313244876A5063078489 @default.
• W4313244876 hasAuthorship W4313244876A5068695530 @default.
• W4313244876 hasAuthorship W4313244876A5071827015 @default.
• W4313244876 hasAuthorship W4313244876A5078656388 @default.
• W4313244876 hasAuthorship W4313244876A5079913204 @default.
• W4313244876 hasAuthorship W4313244876A5082578432 @default.
• W4313244876 hasBestOaLocation W43132448761 @default.
• W4313244876 hasConcept C126322002 @default.
• W4313244876 hasConcept C151956035 @default.
• W4313244876 hasConcept C167135981 @default.
• W4313244876 hasConcept C203014093 @default.
• W4313244876 hasConcept C2522874641 @default.
• W4313244876 hasConcept C2777813720 @default.
• W4313244876 hasConcept C2779134260 @default.
• W4313244876 hasConcept C38180746 @default.
• W4313244876 hasConcept C65409693 @default.
• W4313244876 hasConcept C71924100 @default.
• W4313244876 hasConcept C72563966 @default.
• W4313244876 hasConceptScore W4313244876C126322002 @default.
• W4313244876 hasConceptScore W4313244876C151956035 @default.
• W4313244876 hasConceptScore W4313244876C167135981 @default.
• W4313244876 hasConceptScore W4313244876C203014093 @default.
• W4313244876 hasConceptScore W4313244876C2522874641 @default.
• W4313244876 hasConceptScore W4313244876C2777813720 @default.
• W4313244876 hasConceptScore W4313244876C2779134260 @default.
• W4313244876 hasConceptScore W4313244876C38180746 @default.
• W4313244876 hasConceptScore W4313244876C65409693 @default.
• W4313244876 hasConceptScore W4313244876C71924100 @default.
• W4313244876 hasConceptScore W4313244876C72563966 @default.
• W4313244876 hasIssue "1" @default.
• W4313244876 hasLocation W43132448761 @default.
• W4313244876 hasLocation W43132448762 @default.
• W4313244876 hasLocation W43132448763 @default.
• W4313244876 hasOpenAccess W4313244876 @default.

• next